Oniria Therapeutics granted SME status by European Medicines Agency

Oniria Therapeutics has been granted Small and Medium Enterprise (SME) status by the European Medicines Agency (EMA) as a preclinical biopharmaceutical company working to develop innovative precision drugs to eliminate persistent tumor cells, which are responsible for patients progressing into fatal phases of cancer.

SME status means that Oniria Therapeutics will receive administrative, regulatory and financial support throughout its drug development process. It is also an important step in the company’s focus on the EU market in the future.

This EMA initiative aims to support companies in order to promote innovation and the development of new medicines for unmet medical needs.